Execution Firing, but New Product Profitability Still Unproven

The 405% YoY PAT jump mirrors Q2 FY26's weakness (PAT ~₹74 Cr on a structurally depressed base). The organic story is cleaner: PAT ₹374.9 Cr is up 21.8% QoQ and represents solid sequential progress. The real operational story lies in three moving parts: (1) ROA expanded 149 basis points year-over-year to 2.18%, driven by margin expansion and falling credit costs; (2) NIM rose 86 basis points to 9.26% despite rising borrowing costs, demonstrating pricing power; and (3) credit cost fell to 2.19% and Stage 3 assets compressed to 1.2%, validating AI-driven underwriting and collections investments. On 10.4% QoQ AUM growth to ₹74,008 Cr, this is solid operational execution.

New product momentum accelerated sharply. Gold loan branches went from 460 in Q1 to 550 in Q2 (90 launched this quarter); management targets ~200 more in FY27, aiming for 750–850 by FY28. Consumer durable dealers scaled to 20,000 across 360 locations (near-doubling in 12 months). Commercial vehicle channel partners expanded to 1,250 across 90+ locations in 13 states. Education consultant network at 700 partners with 35% digital adoption. Prime Personal Loans (PPL 24x7) now represent 42% of personal loan disbursements. The mix shift from traditional to new products (28% of total disbursements vs. ~20% implicit in prior quarter) is faster and more aggressive than peers. Critically, management provided no cohort-level profitability for any new product. When pressed directly, responses deferred to "bundled story" and cross-sell leverage—unquantified and unproven at scale.

The market's reaction tells a clear story of healthy skepticism. Despite strong reported numbers, the stock gained just 0.4% on day 1 of announcement (Oct 9, 2026) and has since fallen 14.58% from its all-time high of ₹511.9, now at ₹437.25. The modest pop and subsequent decline signal the market is questioning whether the inflection is structural or cyclical, and whether new product profitability can sustain the ROA story. The stock sits below its 20-day average (₹451.67) and 50-day average (₹465.4), with RSI at 32.6 (neutral), hinting at neither capitulation nor euphoria.

Institutional flows are mixed. FII ownership rose 75 basis points to 10.96%, and DII rose 461 basis points to 16.74%—net institutional buying. But promoter ownership fell 498 basis points to 59.33%, a significant trim. Most telling: PFL Employee Welfare Trust (a promoter vehicle) sold 47.08 million shares at ₹473.50 near the peak. Simultaneous block buys by Sundaram Mutual Fund (18.7M shares), Morgan Stanley (5.28M), HDFC Life (7.3M), and Helios Mutual Fund (15.8M)—also at ₹473.50—show mutual funds and foreign players adding while promoter sellers meet those bids. This insider distribution at the highs is noteworthy and aligns with market caution.

Volume is increasing despite price decline, signaling active debate rather than consensus resignation. The stock trades 14.58% below its all-time high but is up 21% from the 52-week low (₹361.2), suggesting the recent pullback is a rerating within a longer uptrend, not a reversal. The street is awaiting Q3 results and management commentary on three concrete catalysts: cross-sell adoption pace, new product cohort profitability, and insurance regulation clarity—each could resolve the bull-bear debate.

Organic PAT growth rate (stripping any one-time items). Q2 FY27 delivered ₹374.9 Cr, up 21.8% QoQ—solid. If Q3 FY27 posts similar organic growth (₹450+ Cr to sustain 20%+ QoQ), the operational inflection narrative holds and the stock re-rates higher. If Q3 organic growth slides below 10%, or if new product profitability remains undisclosed, the market will reprice lower, expecting operating leverage payoff further out (FY28) rather than H2 FY27. That single metric—organic QoQ PAT growth—is the tell on whether execution translates to sustainable margin expansion or cyclical strength on a weak base.